top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 30 September 2023

Ultrasound Shear Wave Elastography in the Evaluation of Liver Fibrosis

Izhar ud Din, Song Tao

Xinjiang Medical University

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 93-100

Keywords: Ultrasound Shear Wave Elastography (SWE), Liver Fibrosis, Chronic Hepatitis B Virus (HBV) and Hepatitis C


Background: Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading etiology of cirrhosis and liver cancer globally. In China, chronic hepatitis B has grown to be a significant public health issue. NAFLD (non-alcoholic fatty liver disease) is one of the primary causes of cirrhosis in the globe. Up to 10.3% of NAFLD patients, according to the National Health and Nutrition Examination Survey, had advanced fibrosis. These findings suggest that the real-time Shear wave elastography (SWE) can be used for the assessment of significant fibrosis, sever fibrosis and Cirrhosis. Objective: To determine the ultrasound shear wave elastography in the evaluation of liver fibrosis. Methods: A cross-sectional study was conducted at First affiliated hospital of Xinjiang Medical university, which was performed between January 2020 and March 2023. The total patients in our study was 118. In 118 consecutive patients who underwent Ultrasound Shear wave elastography (SWE) before their scheduled liver biopsy (59 men, 59 women). We used Michael Mindray ultrasound machine and its frequency was C6-1. The stages of liver fibrosis according to the METAVIR classification system. Results: F2 stage of fibrosis is more as compare as compare to others. Liver fibrosis is more common in females as comapre to males. According to the age males have higher risk as compare to females. Total patients in our study was 118. Mean age for males patienst were 44.8983 and for females 48.9492. MEAN±SD of Alanine aminotransferase (ALT) was 92.6±116.14 u/L. The frequency of patients with F0 was 33 (28.0 %), F1 was 5 (4.2%), F2 was 58 (49.2%), F3 was 9 (7.6%) F4 was 13 (11.0%). Frequency of no fatty liver was 49, mild fatty liver was 39, moderate fatty liver was 8, sever fatty liver was 22. Hepatitis B was present in 96 patients and was not present in 22 patients out of 118. Hepatitis C was present in 116 patients and was not present in 2 patients out of 118 (1.7). P-value of hepatitis B is 0.34. P-value of hepatitis C is 1.0. P-value of stages of Liver fibrosis with respect to gender is 0.005. Conclusion: Our result concluded that fibrosis stage F2 patients are more in our study (Heaptitis B). Liver fibrosis is more common in females as comapre to males. According to the age males have higher risk as compare to females. Shear wave elastography (SWE) is a straightforward, quick, and repeatable technique for noninvasively assessing liver fibrosis. Benefits include its low cost and global availability.


  1. Barr, R. G., Wilson, S. R., Rubens, D., Garcia-Tsao, G., & Ferraioli, G. (2020). Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology, 296(2), 263–274.

  2. Bamber, J., Cosgrove, D., Dietrich, C. F., Fromageau, J., Bojunga, J., Calliada, F., Cantisani, V., Correas, J. M., D'Onofrio, M., Drakonaki, E. E., Fink, M., Friedrich-Rust, M., Gilja, O. H., Havre, R. F., Jenssen, C., Klauser, A. S., Ohlinger, R., Saftoiu, A., Schaefer, F., Sporea, I., … Piscaglia, F. (2013). EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall in der Medizin (Stuttgart, Germany : 1980), 34(2), 169–184.

  3. Bohte, A. E., de Niet, A., Jansen, L., Bipat, S., Nederveen, A. J., Verheij, J., Terpstra, V., Sinkus, R., van Nieuwkerk, K. M., de Knegt, R. J., Baak, B. C., Jansen, P. L., Reesink, H. W., & Stoker, J. (2014). Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. European radiology, 24(3), 638–648.

  4. Fernández-Salazar, L., Velayos, B., Aller, R., Lozano, F., Garrote, J. A., & González, J. M. (2011). Percutaneous liver biopsy: patients' point of view. Scandinavian journal of gastroenterology, 46(6), 727–731.

  5. Friedrich-Rust, M., Ong, M. F., Martens, S., Sarrazin, C., Bojunga, J., Zeuzem, S., & Herrmann, E. (2008). Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology, 134(4), 960–974.

  6. Grgurevic, I., Puljiz, Z., Brnic, D., Bokun, T., Heinzl, R., Lukic, A., Luksic, B., Kujundzic, M., & Brkljacic, B. (2015). Liver and spleen stiffness and their ratio assessed by real-time two dimensional-shear wave elastography in patients with liver fibrosis and cirrhosis due to chronic viral hepatitis. European radiology, 25(11), 3214–3221.

  7. Goodman Z. D. (2007). Grading and staging systems for inflammation and fibrosis in chronic liver diseases. Journal of hepatology, 47(4), 598–607.

  8. GBD 2017 Cirrhosis Collaborators (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. Gastroenterology & hepatology, 5(3), 245–266.

  9. Hsu, Y. C., Huang, D. Q., & Nguyen, M. H. (2023). Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nature reviews. Gastroenterology & hepatology, 20(8), 524–537.

  10. Karkmann, K., Piecha, F., Rünzi, A. C., Schulz, L., von Wulffen, M., Benten, D., Kluwe, J., & Wege, H. (2018). Versorgung bei kompensierter Leberzirrhose 2018 – Evidenzbasierte prophylaktische Maßnahmen [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. Zeitschrift fur Gastroenterologie, 56(1), 55–69.

  11. Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y. C., Torbenson, M. S., Unalp-Arida, A., Yeh, M., McCullough, A. J., Sanyal, A. J., & Nonalcoholic Steatohepatitis Clinical Research Network (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), 41(6), 1313–1321.

  12. Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017). Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PloS one, 12(3), e0173499.

  13. Liu, J. H., Zou, Y., Chang, W., Wu, J., Zou, Y., Xie, Y. C., Lu, Y. P., & Wei, J. (2017). Assessment of Liver Fibrosis Using Real-time Shear-wave Elastography for Patients with Hepatitis B e Antigen-negative Chronic Hepatitis B and Alanine Transaminase <2 Times the Upper Limit of Normal. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 69(5), 254–261.

  14. Lu, L. G., Zeng, M. D., Wan, M. B., Li, C. Z., Mao, Y. M., Li, J. Q., Qiu, D. K., Cao, A. P., Ye, J., Cai, X., Chen, C. W., Wang, J. Y., Wu, S. M., Zhu, J. S., & Zhou, X. Q. (2003). Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World journal of gastroenterology, 9(11), 2574–2578.

  15. Myers, R. P., Fong, A., & Shaheen, A. A. (2008). Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver international: official journal of the International Association for the Study of the Liver, 28(5), 705–712.

  16. Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A. (2011). Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.), 54(1), 344–353.

  17. Samir, A. E., Dhyani, M., Vij, A., Bhan, A. K., Halpern, E. F., Méndez-Navarro, J., Corey, K. E., & Chung, R. T. (2015). Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology, 274(3), 888–896.

  18. Toyoda, H., Kumada, T., Kamiyama, N., Shiraki, K., Takase, K., Yamaguchi, T., & Hachiya, H. (2009). B-mode ultrasound with algorithm based on statistical analysis of signals: evaluation of liver fibrosis in patients with chronic hepatitis C. AJR. American journal of roentgenology, 193(4), 1037–1043.

  19. Tuguntaev, R. G., Hussain, A., Fu, C., Chen, H., Tao, Y., Huang, Y., Liu, L., Liang, X. J., & Guo, W. (2022). Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations. Journal of nanobiotechnology, 20(1), 236.

  20. Ullah, A., Chen, G., Yibang, Z., Hussain, A., Shafiq, M., Raza, F., Liu, D., Wang, K., Cao, J., & Qi, X. (2022). A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomaterials science, 10(10), 2650–2664.

  21. Vernon, G., Baranova, A., & Younossi, Z. M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics, 34(3), 274–285.

  22. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.), 64(1), 73–84.

  23. Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews. Gastroenterology & hepatology, 15(1), 11–20.

  24. Yasaka, K., Akai, H., Kunimatsu, A., Abe, O., & Kiryu, S. (2018). Deep learning for staging liver fibrosis on CT: a pilot study. European radiology, 28(11), 4578–4585.

  25. Yanguas, S. C., Cogliati, B., Willebrords, J., Maes, M., Colle, I., van den Bossche, B., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A. F., Leclercq, I., & Vinken, M. (2016). Experimental models of liver fibrosis. Archives of toxicology, 90(5), 1025–1048.

  26. Zheng, Y., Wu, J., Ding, C., Xu, K., Yang, S., & Li, L. (2020). Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study. Virology journal, 17(1), 132.

bottom of page